Hot Flashes Market expected to rise | Key Companies – Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology

Hot Flashes Market expected to rise | Key Companies - Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology
Hot Flashes Market
DelveInsight’s “Hot Flashes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hot Flashes, historical and forecasted epidemiology as well as the Hot Flashes market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Hot Flashes market growth is driven by factors like increase in the prevalence of Hot Flashes, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Hot Flashes market report also offers comprehensive insights into the Hot Flashes market size, share, Hot Flashes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hot Flashes market size growth forward. 

Some of the key highlights from the Hot Flashes Market Insights Report:

  • Several key pharmaceutical companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others, are developing novel products to improve the Hot Flashes treatment outlook. 
  • The total Hot Flashes market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Hot Flashes market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Hot Flashes Market Landscape

Hot Flashes Overview 

Hot flashes are an exaggerated and rapid response of the body to dissipate heat. They involve profuse sweating, peripheral vasodilation (widening of blood vessels in the extremities), and a sensation of intense internal heat. These Hot Flashes are triggered by slight increases in core body temperature within a narrowed thermoneutral zone, which is the range of Tc between the upper threshold (sweating) and lower threshold (shivering) for thermoregulation.

During menopause, Hot Flashes are the most common symptom experienced by women, affecting over 80% of them. They are characterized by brief episodes of intense warmth accompanied by sweating, flushing, and sometimes chills. HFs can cause significant distress, especially when they are severe and frequent.

Several factors have been associated with an increased incidence of HFs, although only a few show consistent associations. These factors include obesity, African descent, lower socioeconomic status, presence of premenstrual syndrome, sedentary lifestyle, and smoking. Hot Flashes are characterized by excessive dilation of peripheral blood vessels, which is the body’s attempt to release heat, in the context of an abnormal hypothalamic thermoneutral zone. In women with HFs, even a small increase in core body temperature of 0.4°C can trigger the vasodilatory response, leading to profuse sweating and the sensation of intense heat.

Do you know the treatment paradigms for different countries? Download our Hot Flashes Market Sample Report

Recent Highlights from the Hot Flashes Market Report:

  • Fervent Pharmaceuticals recently commenced a Phase II clinical trial called the M2S Hot Flash Study, conducted virtually from participants’ homes. The trial aims to evaluate a new product’s effectiveness in alleviating moderate to severe symptoms of hot flashes, night sweats, and nocturnal awakenings caused by hot flashes in women during peri- and post-menopause.
  • On another note, Veru Inc, a company focused on developing innovative treatments for prostate cancer, announced positive interim results from a Phase 2 clinical study involving Zuclomiphene citrate. This nonsteroidal oral estrogen receptor agonist is being investigated for its potential in managing hot flashes induced by androgen deprivation hormone therapy (ADT) in men with advanced prostate cancer. The preliminary findings indicate that Zuclomiphene is well tolerated, as there have been no reports of serious or severe adverse events related to the drug. Furthermore, there were no notable observations of adverse events of special interest, such as breast enlargement or pain, or venothromboembolic events (blood clots in the legs or lungs, or stroke) in the safety database of the Phase 2 study.

Hot Flashes Epidemiology Segmentation 

DelveInsight’s Hot Flashes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hot Flashes historical patient pools and forecasted Hot Flashes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hot Flashes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Hot Flashes Prevalence 
  • Age-Specific Hot Flashes Prevalence 
  • Gender-Specific Hot Flashes Prevalence 
  • Diagnosed and Treatable Cases of Hot Flashes

Visit for more @ Hot Flashes Epidemiological Insights

Hot Flashes Treatment Market 

The Hot Flashes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hot Flashes market trends by analyzing the impact of current Hot Flashes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Hot Flashes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hot Flashes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hot Flashes market in 7MM is expected to witness a major change in the study period 2019-2032.

Hot Flashes Emerging Drugs

Fezolinetant: Astellas Pharma

Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.

Elinzanetant: Bayer

Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes.

Fezolinetant: Ogeda

Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women’s health disorders. Fezolinetant’s mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women. In addition, fezolinetant addresses the cause of PCOS by selectively lowering luteinizing hormone (LH) without affecting follicle-stimulating hormone (FSH) in order to restore the correct LH-to-FSH ratio and permit the restoration of menstrual cycle regularity and fertility. Fezolinetant is also superior to the existing, marketed gonadotropin-releasing hormone (GnRH) ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis.

Zuclomiphene citrate: Veru Inc

Zuclomiphene citrate is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist. Today the Company announced that a Phase 2 clinical trial of Zuclomiphene citrate demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes in men with advanced prostate cancer on ADT therapy.

Hot Flashes Key Companies

  • Veru Healthcare
  • Fervent Pharmaceuticals
  • Ogeda
  • Bayer
  • Lundbeck A/S
  • TherapeuticsMD
  • MenoGeniX
  • Mitsubishi Tanabe Pharma
  • QUE Oncology
  • Pherin Pharmaceuticals

For more information, visit Hot Flashes Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Hot Flashes Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Hot Flashes, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Hot Flashes epidemiology in the 7MM
  • Hot Flashes marketed and emerging therapies 
  • Hot Flashes companies
  • Hot Flashes market drivers and barriers 

Key Questions Answered in the Hot Flashes Market Report 2032:

  • What was the Hot Flashes market share distribution in 2019, and how would it appear in 2032?
  • What is the total Hot Flashes market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Hot Flashes market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Hot Flashes market projected to expand at 7MM?

Table of Contents:

1 Hot Flashes Market Key Comprehensive Insights 

2 Hot Flashes Market Report Introduction

3 Competitive Intelligence Analysis for Hot Flashes

4 Hot Flashes Market Analysis Overview at a Glance

5 Executive Summary of Hot Flashes

6 Hot Flashes Epidemiology and Market Methodology

7 Hot Flashes Epidemiology and Patient Population

8 Hot Flashes Patient Journey

9 Hot Flashes Treatment Algorithm, Hot Flashes Current Treatment, and Medical Practices

10 Key Endpoints in Hot Flashes Clinical Trials

11 Hot Flashes Marketed Therapies 

12 Hot Flashes Emerging Therapies

13 Hot Flashes: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Hot Flashes

16 Hot Flashes Market Key Opinion Leaders Reviews

18 Hot Flashes Market Drivers

19 Hot Flashes Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Hot Flashes Epidemiology 2032

DelveInsight’s “Hot Flashes – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hot Flashes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hot Flashes Pipeline 2023

“Hot Flashes Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hot Flashes market. A detailed picture of the Hot Flashes pipeline landscape is provided, which includes the disease overview and Hot Flashes treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States